
Tyra Biosciences, Inc. (TYRA) Stock Ticker
TYRA right now
Market factors today
Unlock the full TYRA picture
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
TYRA stock facts
| Ticker symbol | TYRA |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $1.3B |
| CEO | Todd Harris |
| Employees | 87 |
| Headquarters | Carlsbad, CA, US |
| IPO date | 2021-09-15 |
| Website | www.tyra.bio |
What you can see for TYRA on Tickr
Live TYRA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the TYRA report.
Rankings
FAQ
What is the ticker symbol for Tyra Biosciences, Inc.?
The ticker symbol for Tyra Biosciences, Inc. is TYRA, listed on the NASDAQ Global Select.
What is TYRA?
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is…